Odylia Therapeutics Inc

Atlanta, GA   |  www.odylia.org

Mission

Odylia Therapeutics accelerates therapeutic development for people with rare diseases, changing the way treatments are brought from the lab to the clinic. Our ultimate goal is to bring life changing treatments to people with genetic disease regardless of prevalence or commercial interest.

Ruling year info

2018

CEO

Mr. Scott Dorfman

Main address

1447 Peachtree St NE 7th Floor

Atlanta, GA 30309 USA

Show more contact info

EIN

82-2120760

NTEE code info

Eye Diseases, Blindness and Vision Impairments (G41)

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2019 and 2018.
Register now

Programs and results

What we aim to solve

SOURCE: Self-reported by organization

In the US, 1 in 10 people have a rare disease, yet 95% of rare diseases do not have a single FDA approved drug treatment. This is not acceptable. It is not harder to find treatments for rare diseases-the technology exists. Viable treatments are often shelved because the number of patients who would utilize the treatment is not enough to justify the costs of development. The return on investment is measured in financial profits instead of human benefits. Additionally, research on rare diseases is unfocused because the metrics of success are not geared toward finding a treatment. The results, while interesting, do not achieve the goal of improving the life of patients, so funding and time are not utilized efficiently - leaving patients and their families no closer to a treatment. Odylia Therapeutics works to accelerate the development of therapies for people with rare, genetic diseases and change the way treatments are brought from the lab to the clinic and, then, ultimately to patients.

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Research and Development

Striving to find treatments for rare eye disease, Odylia Therapeutics is dedicated to facilitating the movement of science from the lab into the clinic to save vision for those going blind due to Inherited Retinal Disease. Our mission is to change the paradigm of how rare disease treatments are brought through clinical trials.

Population(s) Served
Adults

Where we work

Our results

SOURCE: Self-reported by organization

How does this organization measure their results? It's a hard question but an important one.

Number of organizational partners

This metric is no longer tracked.
Totals By Year
Population(s) Served

Health

Related Program

Research and Development

Type of Metric

Outcome - describing the effects on people or issues

Direction of Success

Increasing

Number of groups/individuals benefiting from tools/resources/education materials provided

This metric is no longer tracked.
Totals By Year
Population(s) Served

Health

Related Program

Research and Development

Type of Metric

Outcome - describing the effects on people or issues

Direction of Success

Increasing

Our Sustainable Development Goals

SOURCE: Self-reported by organization

Learn more about Sustainable Development Goals.

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

Odylia works to bring life-changing therapies to people with rare diseases - accelerating and de-risking the process to get treatments from the lab through clinical trials to patients. We remove roadblocks that might delay or stop a potential treatment, creating innovative collaborations to ensure drug development for rare disease continuously moves forward.
Work with 6-10 Patient Advocacy Groups each year to create strategic research plans. Patient Advocacy Groups (PAGs) are the primary drivers of rare disease research. They are usually grass-root efforts of patient families who are looking for answers about a rare disease but they often lack scientific knowledge and bandwidth to determine a strategic, streamlined plan to get research from the lab to clinical trials and are left to navigate the process alone. Valuable time and resources are wasted and the groups end up no closer to finding a therapeutic for their patients after years of effort.
Manage the gene therapies we are developing directly and foster creative collaborations to ensure continuous progress toward clinical trials. Currently, Odylia oversees two therapeutic programs that are in preclinical testing. We will continue to further work with contract research organizations, key opinion leaders,vendors, and clinicians to lower costs, maintain timelines, and ensure treatments continue to move forward.
Secure $5-8 million in venture philanthropy to support our Manufacturing Fund. The costs to manufacture materials needed to test therapies are high. In the absence of a commercial partner who would fund these costs, Odylia will seek donors who believe in our mission and desire to see treatments created for people with rare diseases.
Odylia is committed to shifting the paradigm to focus on proven science and the unmet need for rare disease patients to create synergy to drive therapeutic development. The consequence of not doing this work is not only lost opportunity, it is potential loss of life for people diagnosed with a rare disease.

Working with Patient Advisory Groups: We will help PAGs identify short and long term goals for their research programs or research investments. Patients with a rare disease may want different treatments for symptoms, improved quality of life, or even a cure, understanding these differences and defining the needs for each organization is important for guiding activities. Working with the PAGs, we will provide a therapeutic or research roadmap, experimental plan (development and oversight), disease area resource gap analysis, key opinion leader engagement, clinical development planning, patient data strategy, program management & operations - dependent on the group’s needs. Odylia will educate and empower PAGs-working together to create and drive strategic research for their disease to better serve the needs of the patients they represent. Moreover, we will help PAGs determine which research may not best serve their goals, and therefore is not the best investment of their resources. PAGs will have increased capacity to create and drive a strategic research program to achieve their goals on behalf of their patients. Their increased capacity will also enable them to better initiate and implement research using the detailed roadmap we provide.
Pipeline Program Management: Odylia Therapeutics has created and is implementing a streamlined and strategic plan to move two gene therapies from preclinical development to clinical trials. Our staff directs the day-to-day work and scientific guidance required to move each therapy forward. We focus on completing the research that is specifically aimed at proving the treatment is safe and effective and does not digress to answer interesting but not useful scientific questions. The work includes proof-of-concept studies, IND-enabling studies, coordinating the manufacturing process for materials needed for studies, and clinical development activities. We work with a network of for-profit companies to innovatively align interests and expertise creating strategic partnerships with third party vendors who provide their services to Odylia at a discount, enabling us to produce therapies as a significantly reduced price. Odylia leverages our nonprofit designation to keep costs low.
Manufacturing Funding: Rare disease treatments often stall because there is no commercial interest. One of the longest and most expensive stages of getting a treatment to patients is the manufacturing process. Odylia is actively seeking donors to support our Manufacturing Fund. A Development Manager was hired in October 2020 to focus on building philanthropic support. Donations to this fund will ensure that therapeutic materials are produced promptly, and the treatments can continue moving, reaching clinical trials and the patients as soon as possible.

Potential profit should not be the delineation for a life-altering therapy to be developed. Promising treatments for rare diseases should be moved from the lab to clinical trials no matter the

Odylia is led by Chief Scientific Officer Ashley Winslow, PhD. She received her PhD in Medical Genetics from the University of Cambridge and completed her postdoctoral work at Massachusetts General Hospital and Harvard Medical School. Ashley has extensive experience engaging stakeholders especially in the rare disease community. At Pfizer, she worked with patient communities to design more effective clinical trials. While at Univ of Pennsylvania, she worked at the Orphan Disease Center (ODC) with a wide variety of patient groups on all aspects of research and drug-development implementation including scientific advisement, diversifying research portfolios, budgeting, contracting, assembling advisory boards, engaging key opinion leaders, vendor selection, patient engagement, and clinical trial design. She founded and led ODC’s International Patient Registry and Natural History Study Initiative to harness human-derived data to support community-wide research and clinical development across rare diseases and the JumpStart program to guide Patient Groups just starting research initiatives. At Penn she was a ‘CSO on loan’ to the Loulou Foundation.

The Director of Program Management, Madison Grant, received her PhD in Cellular Biology from the University of Georgia. She has focused on both retinal and central nervous system development. Most recently, she studied the effects of heterozygous loss-of-function mutations in nervous system development and maintenance for a rare, genetic disease, aniridia. Madison has experience in cell and gene therapy and advanced neuroimaging modalities. She provides scientific guidance as well as operational strategy to facilitate execution of Odylia programs.

Our CEO, Scott Dorfman serves as an Operations Partner for Fulcrum Equity Partners and sits on the Board of Dropoff Inc., Complemar Corporation, Fulcrum Equity, and Usher 2020 Foundation. Prior to Odylia, Mr. Dorfman founded and was Chairman, & CEO of Innotrac Corporation (NASDAQ: INOC), which was a full-service provider of eCommerce technology, fulfillment, and call center services until combining with eBay Enterprises to form Radial Corporation. Scott is father of two children with a rare disease called Usher Syndrome and runs a separate foundation focused on raising funds for research for this disorder.

Odylia’s cofounder, Luk Vandenberghe, PhD, is Assistant Professor, Harvard Medical School and Director, Grousbeck Gene Therapy Center, Massachusetts Eye and Ear. He has discovered and developed new technologies in the gene therapy field and started numerous companies to bring treatments to patients. His work has focused on a number of rare genetic disorders and the delivery of functional genes to treat these disorders.

The Odylia Board of Directors and Advisory Board members have vast knowledge and experience in the rare disease field. They are also instrumental in guiding our work to achieve our mission.

Odylia Therapeutics began working on a drug development program for Leber Congenital Amaurosis (LCA) type 6 caused by mutations in the RPGRIP1 gene, in 2019. In the last two years, we put together a strategic research plan, sourced vendors, created the experimental plans, reviewed and interpreted outcomes, and established a Clinical Development plan. Because of Odylia, this therapy is ready for late-stage preclinical testing. We are focused on identifying funding for manufacturing of the gene therapy for clinical trials and beginning engagement with the FDA to prepare for clinical trials.

In June 2020, Odylia partnered with patient advocacy groups to develop a gene therapy to treat vision loss in patients with Usher Syndrome caused by mutations of the USH1C gene. We have identified the academic collaborators, recruited a clinical advisory board and research vendors, created strategic research and program risk mitigation plans, and managed the experimental execution. We are working with our partners to manufacture a gene therapy and generate proof-of-concept data to assess the preliminary efficacy of the gene therapy.
In 2021, Odylia will oversee the pharmtox, manufacturing, and clinical development for rpgrip1; initiate proof of concept testing for ush1c, and work with 3-4 additional organizations to create strategic research plans.

Financials

Odylia Therapeutics Inc
lock

Unlock financial insights by subscribing to our monthly plan.

Subscribe

Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more about GuideStar Pro.

Operations

The people, governance practices, and partners that make the organization tick.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

Odylia Therapeutics Inc

Board of directors
as of 4/1/2021
SOURCE: Self-reported by organization
Board chair

Scott Dorfman

Luk Vandenberghe

Mass Eye & Ear, Harvard Medical School

Emil Kakkis

Ultragenyx Pharmaceutical Inc

Mat Pletcher

Audentes Therapeutics

Organizational demographics

SOURCE: Self-reported; last updated 03/11/2021

Who works and leads organizations that serve our diverse communities? GuideStar partnered on this section with CHANGE Philanthropy and Equity in the Center.

Leadership

The organization's leader identifies as:

Race & ethnicity
White/Caucasian/European
Gender identity
Male

Race & ethnicity

No data

Gender identity

No data

 

No data

Sexual orientation

No data

Disability

No data